Destiny Pharma looking to move on to phase III with XF-73 nasal gel
News release
by
Destiny Pharma PLC
London, UK
|
March 27, 2023 08:31 AM Eastern Daylight Time
Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) chief executive Neil Clark speaks to Thomas Warner from Proactive after publishing research about the company's new nasal gel, called XF-73, in the US journal 'Infection Control & Hospital Epidemiology'.
Clark explains more about the benefits of the gel and how it works, and confirms that the plan is to find a partner to help fund a phase III study.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
